Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceralasertib monotherapy versus ceralasertib plus durvalumab in advanced melanoma resistant to PD-(L)1 inhibition
2024-512378-91-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Aug 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised, open-label trial in melanoma comparing Ceralasertib monotherapy with Ceralasertib plus durvalumab (2 arms). Primary endpoints: Objective response rate and CD8-positive T-cell tumor infiltration. Planned start Aug 2024; status: authorised.
02
Drugs
ceralasertibdurvalumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2024-512378-91-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512378-91-00.